Kamu erişimi zorunlu olan makaleler - Alessio AmatuDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 4
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
Zorunlu olanlar: European Commission
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies
G Mauri, EG Pizzutilo, A Amatu, K Bencardino, L Palmeri, EF Bonazzina, ...
Cancer treatment reviews 73, 41-53, 2019
Zorunlu olanlar: European Commission
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression
RJP Bonnal, G Rossetti, E Lugli, M De Simone, P Gruarin, J Brummelman, ...
Nature immunology 22 (6), 735-745, 2021
Zorunlu olanlar: Cancer Research UK, Government of Italy, AIRC Foundation for Cancer Research …
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
G Mauri, V Gori, E Bonazzina, A Amatu, F Tosi, K Bencardino, L Ruggieri, ...
Cancer Treatment Reviews 91, 102112, 2020
Zorunlu olanlar: Cancer Research UK, European Commission, Government of Italy, AIRC …
Bir yerde sunuluyor: 36
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
Zorunlu olanlar: US National Institutes of Health, Government of Spain, Government of Italy
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
Zorunlu olanlar: US National Institutes of Health
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
Zorunlu olanlar: US National Institutes of Health
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
Zorunlu olanlar: European Commission, Government of Italy, AIRC Foundation for Cancer …
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
Zorunlu olanlar: Government of Italy
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena
Annals of Oncology 30, viii5-viii15, 2019
Zorunlu olanlar: European Commission, AIRC Foundation for Cancer Research in Italy
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
Zorunlu olanlar: Government of Italy
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
Zorunlu olanlar: US National Institutes of Health, European Commission, Government of Spain …
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
Zorunlu olanlar: European Commission, Government of Italy
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
Zorunlu olanlar: Government of Italy
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ...
Nature Medicine 28 (8), 1612-1618, 2022
Zorunlu olanlar: Cancer Research UK, European Commission, Government of Italy, AIRC …
HER2 positivity predicts unresponsiveness to EGFR‐targeted treatment in metastatic colorectal cancer
A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ...
The oncologist 24 (10), 1395-1402, 2019
Zorunlu olanlar: European Commission
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
Zorunlu olanlar: Government of Italy
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin
S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ...
Clinical Cancer Research 26 (6), 1372-1384, 2020
Zorunlu olanlar: Cancer Research UK, European Commission, Government of Italy, AIRC …
Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer
F Tosi, A Sartore-Bianchi, S Lonardi, A Amatu, F Leone, S Ghezzi, ...
Clinical colorectal cancer 19 (4), 256-262. e2, 2020
Zorunlu olanlar: European Commission, Government of Italy, AIRC Foundation for Cancer …
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
G Mauri, E Bonazzina, A Amatu, F Tosi, K Bencardino, V Gori, ...
Cancers 13 (1), 137, 2021
Zorunlu olanlar: European Commission, Government of Italy, AIRC Foundation for Cancer …
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir